1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS

Ionis-Partnered Asset Developed For SOD1 Genetic Mutations

 
• By Mandy Jackson

The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.

Illuminated oil lamp on fence along woodland path
Biogen will seek guidance from regulators and others that may illuminate a path forward for tofersen in ALS • Source: Alamy

Tofersen never was going to be a large-market, major revenue-driving drug for Biogen, Inc. But with multiple setbacks over the last several months plus commercial challenges, disappointing Phase III results for the drug in amyotrophic lateral sclerosis (ALS) patients with a superoxide dismutase 1 (SOD1) gene mutation is another badly timed setback for the company and its partner, Ionis Pharmaceuticals, Inc.

Top-line results from the Phase III VALOR clinical trial and an open-label extension study of tofersen – an antisense oligonucleotide...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from R&D

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.